# RADIANCE Continued Access Protocol

Study · id `cardio:ct-nct05017935` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05017935](<https://clinicaltrials.gov/study/NCT05017935>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05017935

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT05017935. Allocation not applicable; no masking; primary purpose treatment. Start 2022-05-04 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT05017935, source copy `cardio:ctgov-nct05017935-2024-06-17`, retrieved 2026-10-26)
- Started: 2022-05-04 (actual) (ClinicalTrials.gov record NCT05017935, source copy `cardio:ctgov-nct05017935-2024-06-17`, retrieved 2026-10-26)
- Primary completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT05017935, source copy `cardio:ctgov-nct05017935-2024-06-17`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT05017935, source copy `cardio:ctgov-nct05017935-2024-06-17`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05017935, source copy `cardio:ctgov-nct05017935-2024-06-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05017935-2024-06-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: RADIANCE Continued Access Protocol
- Acronym: RADIANCE CAP
- Condition: Hypertension
- Condition: Hypertension, Resistant to Conventional Therapy
- Condition: Vascular Diseases
- Condition: Cardiovascular Diseases
- Intervention (Device): Renal Denervation
- Lead sponsor: ReCor Medical, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: ReCor Medical, Inc. (`cardio:org-recor-medical-inc`)

## Provenance

Content hash: 009fe8b558e746df54574a837ecfa19c92b989aebf80b6d83bcbc4b59fe5bc10
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
